Received: 4 May 2020
Accepted: 5 January 2021
First Online: 19 January 2021
Ethics approval and consent to participate
: This study was approved by the ethics commission of the Berlin Chamber of Physicians (Ref: Eth-14/18). All participants had to provide informed consent through the survey website before starting the survey.
: Not applicable.
: HJ received payment for study cost from Gilead Sciences Inc. UK owns ‘Exchange-traded fund’ (ETF) shares, which may include stocks of pharmaceutical companies that produce or develop PrEP. The other authors declare no conflicts of interest.